Since joining Aravis in 2001, Simon Nebel has participated in the financing of a number of life science companies and the M&A transactions of a number of Aravis portfolio companies. Most recently he was a co-founder of Aravis Energy I LP, the first Swiss Limited Partnership focused on renewable energy.
Before joining Aravis, Simon was a group strategist at UBS (London, Basel and Zurich), where he coordinated and worked on business planning and modelling. This included developing a Biotechnology Venture Capital business proposal for UBS Capital.
He is currently a board member of SynAffix (NL), MarinoMed (AT), RuiYi Inc. (USA/China), and Leading Swiss Renewable Energy AG and a former member of the board of directors of Borean Pharma (Denmark), ImVision (Switzerland), MerLion Pharmaceutical SA (Switzerland) and secretary of the board of Evolva (Switzerland).
Simon holds a PhD in Biophysics from the Biocentre of the University of Basel (1996) and an MBA with distinction from the London Business School (2001).